The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Using the stereospecific metabolism of (+)- and (-)-bufuralol and (+)- and (-)-metoprolol as model reactions, we have characterized the enzymic deficiency of the debrisoquine/sparteine-type polymorphism by comparing kinetic data of subjects in vivo with their microsomal activities in vitro and with reconstituted activities of cytochrome P-450 isozymes purified from human liver. The metabolism of bufuralol in liver microsomes of in vivo phenotyped 'poor metabolizers' of debrisoquine and/or sparteine is characterized by a marked increase in Km, a decrease in Vmax and a virtual loss of the stereoselectivity of the reaction. These parameters apparently allow the 'phenotyping' of microsomes in vitro. A structural model of the active site of a cytochrome P-450 for stereospecific metabolism of bufuralol and other polymorphically metabolized substrates was constructed. Two cytochrome P-450 isozymes, P-450 buf I and P-450 buf II, both with MW 50,000 Da, were purified from human liver on the basis of their ability to metabolize bufuralol to 1'-hydroxy-bufuralol. However, P-450 buf I metabolized bufuralol in a highly stereoselective fashion ((-)/(+) ratio 0.16) as compared to P-450 buf II (ratio 0.99) and had a markedly lower Km for bufuralol. Moreover, bufuralol 1'-hydroxylation by P-450 buf I was uniquely characterized by its extreme sensitivity to inhibition by quinidine. Antibodies against P-450 buf I and P-450 buf II inhibited bufuralol metabolism in microsomes and with the reconstituted enzymes. Immunochemical studies with these antibodies with microsomes and translations in vitro of RNA from livers of extensive and poor metabolizers showed no evidence for a decrease in the recognized protein or its mRNA. Because the antibodies do not discriminate between P-450 buf I and P-450 buf II, both a decreased content of P-450 buf I or its functional alteration could explain the polymorphic metabolism in microsomes. The genetically defective stereospecific metabolism of mephenytoin was determined in liver microsomes of extensive and poor metabolizers of mephenytoin phenotyped in vivo. Microsomes of poor metabolizers were characterized by an increased Km and a decreased Vmax for S-mephenytoin hydroxylation as compared to extensive metabolizers and a loss of stereospecificity for the hydroxylation of S-versus R-mephenytoin. A cytochrome P-450 with high activity for mephenytoin 4-hydroxylation was purified from human liver. Immunochemical studies with inhibitory antibodies against this isozyme suggest the presence in poor-metabolizer microsomes of a functionally altered enzyme.

[1]  R. Cooper,et al.  OXIDATION POLYMORPHISM HAS CLINICAL RELEVANCE , 1984, The Lancet.

[2]  P. Meier,et al.  Hepatic Monooxygenase Activities in Subjects With a Genetic Defect in Drug Oxidation , 1983 .

[3]  P. Meier,et al.  Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine‐type polymorphism of drug oxidation , 1984, European journal of clinical investigation.

[4]  A. Boobis,et al.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. , 1985, Biochemical pharmacology.

[5]  M. Eichelbaum.  Defective Oxidation of Drugs: Pharmacokinetic and Therapeutic Implications , 1982, Clinical pharmacokinetics.

[6]  P. Beaune,et al.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.

[7]  D. Nebert,et al.  Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution. , 1982, Biochemical pharmacology.

[8]  A. Ashworth,et al.  Isolation and sequence of a human cytochrome P-450 cDNA clone. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. Kalow.  The genetic defect of mephenytoin hydroxylation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[10]  T. Kronbach,et al.  Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: in vivo — in vitro correlations , 1985 .

[11]  T. Kronbach,et al.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers. , 1984, Biochemical and biophysical research communications.

[12]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[13]  J. Idle,et al.  PROTECTING POOR METABOLISERS, A GROUP AT HIGH RISK OF ADVERSE DRUG REACTIONS , 1983, The Lancet.

[14]  F. Guengerich,et al.  Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Kronbach,et al.  Debrisoquine‐type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation , 1984, FEBS letters.